197 results about "Bronchiectasis" patented technology

The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.

The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.

The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airnvays distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

This invention relates to methods of treating pulmonary diseases in patients that beta adrenergic receptor agonist therapy is not effective. The method comprises the steps of: identifying a patient who suffers from a pulmonary disease and has reduced responsiveness to treatment with one or more beta adrenergic receptor agonists, and administering to the patient an effective amount of a Rho kinase inhibitor compound, wherein said pulmonary disease is selected from the group consisting of: asthma, chronic obstructive pulmonary disease, respiratory tract illness caused by respiratory syncytial virus infection such as RSV-induced wheezing, airway hyperreactivity, or bronchiolitis, bronchiectasis, alpha-1-antitrypsin deficiency, lymphangioleiomyomatosis, cystic fibrosis, bronchiolitis or wheezing caused by agents other than respiratory syncytial virus, chronic bronchitis, and occupational lung diseases.

The invention relates to a healthy tea and preparation method thereof, specially to a healthy tea for treating asthma cough and preparation method thereof. Asthma cough is a common respiratory disease, and the disease can be caused by trachitis, emphysema, pulmonary heart disease, bronchiectasis, pulmonary fibrosis, and pneumoconiosis; the incidence of asthma cough is highest when climate is dry or cold in spring and winter, and the disease is most common in middle-aged and aged people. Taking traditional Chinese medicine theories as a guide and combining with the long-history Chinese tea drink culture, the healthy tea for treating asthma cough of the present invention is elaborately prepared from main materials of tea and honey, and medicinal materials of glycyrrhiza, bamboo leaf, sterculia lychnophora, loquat leaf, rabdosia rubescens, Chinese yam, cinnamon, artemisia capillaries, radix adenophorea, balloonflower, tangerine peel, rhizoma pinelliae, and fritillaria. The healthy tea can effectively improve human immunity, eliminate inflammations in pulmonary tracheae and bronchus, so that treatment effects of dispersing phlegm, dispelling crux, relieving asthma and stopping cough are achieved.

The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjôgren's Syndrome, and other CFTR associated disorders.

The present invention relates to the compound of the formula:or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.

The present invention relates to the compound of the formula:or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.

The present invention relates to the compound of the formula:or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.

The invention discloses the drug of treating the nasal over-secretion and chronic obstructive emphysema, at the mean time, provides the drug compositions of treating the nasal over-secretion and chronic obstructive emphysema, which are aerosol, powder cloud agent, naristillae and spray. In the invention, the compositions, which are introduced quaternary ammonium group on the basis of penehyclidine hydrochloride, can't permeate membrane and enter into the circulatory system and central, so it can be used in treating the chronic obstructive emphysema. Besides, due to the low absorptivity in the mucous membrane position, the said new compositions are extended the resistance time at local, so it can be used in treating the chronic obstructive emphysema and coryza.

The invention discloses an orally disintegrating tablet of ambroxol hydrochloride and a preparation method thereof, which can effectively treat acute and chronic respiratory diseases (such as thick sputum and expectoration difficulty due to acute and chronic bronchitis, bronchial asthma, bronchiectasis, tuberculosis and the like.) The invention aims to provide an orally disintegrating tablet of ambroxol hydrochloride for wide patients and medical staff, i.e. a new preparation of a clinical medicine, which has rapid absorption, high bioavailability, no water for taking, little side effect and more convenience and is prepared by using ambroxol hydrochloride as a raw material, adding some special kinds of accessories in a certain proportion according to a technical measure disclosed in the invention. The product of the invention has sweet and fragrant taste, rapid effect and high bioavailability and is particularly easy to improve the drug compliance of patients.

The invention relates to a doxofylline-containing liquid injection used for treating bronchiectasis, and provides the doxofylline with higher concentration. The injection comprises doxofylline, a water solvent, and a pH value regulating agent. The injection comprises the following components by weight percentage: 1 to 4 percent of the doxofylline, and 0.01 to 5 percent of the pH value regulating agent. The injection enriches specifications of the prior doxofylline injection, and brings convenience to the clinical application. The invention also provides a preparation method and a quality control method for the doxofylline liquid injection. Relevant materials in the doxofylline injection can be determined by an HPLC method to improve the product controllability.

Dry powder vancomycin compositions and methods for administering and preparing such compositions. A composition of the present disclosure may be administered to a subject via pulmonary administration in an amount effective to treat and / or prevent a bacterial infection in the subject. Administration of an effective amount of a composition of the present disclosure may be particularly useful in treating a gram-positive bacterial infection in a subject suffering from pneumonia, cystic fibrosis, bronchiectasis, or other chronic lung disease with a bacterial infection of the subject's airway and / or lung.

A pharmaceutical composition is provided, where the pharmaceutical composition contains formula (I), (II), or (III) flavonoids which possess selective phosphodiesterase 4 or 4 / 3 inhibition, as a main ingredient. Especially, this composition is used in the treatment of asthma, chronic obstructive pulmonary disease (COPD), or chronic inflammation, and has bronchodilatory effects. In addition, whether the above-mentioned flavonoids have side effects, such as nausea, vomiting, gastric hypersecretion, etc., in accordance with their binding to high affinity rolipram binding sites (HARBS) of particulates of brain cells are disclosed.

The invention relates to a Chinese traditional medicament composition medicament for curing bronchiectasis and process for preparation. The process for preparation is that according to the mass ratio6:3:2:2, the invention uses cuttlefish bone, the root of herba sedum aizoon, rhubarb and coptis chinensis, wherein the cuttlefish bone is fried into slight yellow, and the materials are separately comminuted into 120 orders fine particles and combined; according to the mass ratio 6:6:6:6:6:6:6:6:6:12:6:4, the invention employs scutellaria, phellodendron, capejasmine, achyranthes aspera, sophora flavescens ait, balloonflower, fritillaria, almond, pinellia ternate, radix pseudostell, liriope and glycyrrhiza uralensis, wherein the medicaments above are decocted in the water for three times, and the medical solutions are combined, deposited to decontaminate the impurities, and concentrated into the paste shape; and according to the mass ratio 1:1, the comminuted fine particles and the concentrated pasty material are separately taken to combine, mix homogeneously and dry, and then the drying medicament is made into pills through the comminuting, the watering, the pills and the drying. The invention has the functions of replenishing qi, clearing heat, nourishing yin, diminishing inflammation, drying dampness, eliminating phlegm, stopping bleeding, and activating blood and dissolving stasis. Moreover, the invention has quick execution and high cure rate for curing lung-heat type expectoration and hemoptysis of bronchiectasis.

Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and / or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.

The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.